Latest filing published 25 Mar 2025 for Lyell Immunopharma, Inc., €106k.
Filing timeline
BuySaleInsider track record
No signal scores available.
Closed purchases
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- +81.2%Entry US$11.16 · Close at T+365 US$20.22
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Sumant Ramachandra: trading record in brief
Filings by Sumant Ramachandra span 3 companies, the busiest being Hospira Inc, Lyell Immunopharma, Inc. and Madrigal Pharmaceuticals, Inc. Between 30 September 2008 and 21 March 2025, the trades on record add up to 29 filings.
In open-market terms, that means 1 purchase worth €106k on one side and 3 sales worth €4.5M on the other. The net balance comes to €4.4M on the selling side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 16 share grants and 6 option exercises. In 2025 alone, the filings show 1 purchase and no sales.
The newest entry dates from 25 March 2025: an open-market purchase of €106k, in Lyell Immunopharma, Inc. The median gap between a trade and its publication by SEC (Form 4) is 4 days. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Sumant Ramachandra
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 200,000 shares@ US$0.5761100.0% of flowCommon StockSEC:0001415889-25-008942:0Canonical exit: 19 Jun 2025 (T+90)
- 271 shares@ US$90.00Common StockSEC:0001179110-15-013011:0
- 14,922 shares0Common StockSEC:0001179110-15-013011:1
- 17,142 shares0Common StockSEC:0001179110-15-013011:2
- 12,230 shares0Common StockSEC:0001179110-15-013011:3
- 9,101 shares0Common StockSEC:0001179110-15-013011:4
- 58,531 shares@ US$37.36Common StockSEC:0001179110-15-013011:5
- 59,259 shares@ US$42.70Common StockSEC:0001179110-15-013011:6
- 230,494 shares@ US$90.00Common StockSEC:0001179110-15-013011:7
- 2,161 shares@ US$88.81Common StockSEC:0001179110-15-010375:0
- 1,619 shares@ US$87.54Common StockSEC:0001179110-15-004284:0
- 34,480 shares@ US$87.50Common StockSEC:0001179110-15-003631:0
- 1,925 shares@ US$50.88Common StockSEC:0001179110-14-011083:0
- 22,639 shares0Common StockSEC:0001179110-14-004052:0
- 17,844 shares0Common StockSEC:0001179110-13-011316:0
- 23,702 shares@ US$35.36Common StockSEC:0001179110-13-010111:0
- 23,702 shares@ US$35.69Common StockSEC:0001179110-13-010111:1
- 75,000 shares0Common StockSEC:0001179110-13-005074:0
- 17,337 sharesCommon StockSEC:0001179110-12-004282:0
- 5,495 shares0Common StockSEC:0001179110-12-004282:1
- 6,218 shares@ US$37.00Common StockSEC:0001179110-11-013918:0
- 79,433 shares@ US$22.15Common StockSEC:0001179110-11-004724:0
- 79,433 shares@ US$53.64Common StockSEC:0001179110-11-004724:1
- 20,029 shares@ US$53.64Common StockSEC:0001179110-11-004724:2
- 6,318 sharesCommon StockSEC:0001179110-11-003582:0
25 of 28 declarations
